Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$33.24
+5.5%
$36.32
$30.17
$60.87
$6.10B0.191.20 million shs2.08 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$62.47
+0.9%
$99.40
$56.88
$173.25
$6.06B0.791.29 million shs3.79 million shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$39.82
+5.5%
$34.94
$12.93
$43.32
$5.93B2.133.07 million shs4.48 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Legend Biotech Co. stock logo
LEGN
Legend Biotech
+5.46%-4.12%+0.79%-4.29%-41.10%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+0.90%-14.28%-38.28%-49.66%-50.81%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%+1.99%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+5.48%-2.38%+15.69%+28.20%+175.76%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.6961 of 5 stars
3.53.00.00.02.91.70.6
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.8474 of 5 stars
4.43.00.04.23.12.51.9
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
3.0584 of 5 stars
1.40.00.03.53.62.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.92
Moderate Buy$79.00137.67% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.83
Moderate Buy$164.05162.60% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.83
Moderate Buy$40.672.13% Upside

Current Analyst Ratings Breakdown

Latest TARO, LEGN, TGTX, and SRPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$75.00 ➝ $75.00
3/31/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$161.00 ➝ $87.00
3/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$105.00 ➝ $80.00
3/19/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$124.00 ➝ $99.00
3/19/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell$75.00 ➝ $75.00
3/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00 ➝ $202.00
3/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$163.00 ➝ $163.00
3/17/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$82.00 ➝ $80.00
3/12/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/12/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$73.00 ➝ $75.00
3/7/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Perform$105.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$627.24M9.73N/AN/A$6.88 per share4.83
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B3.19N/AN/A$9.19 per share6.80
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$329.00M19.01$0.11 per share353.90$1.06 per share37.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$518.25M-$0.48N/AN/AN/A-66.92%-29.69%-19.45%5/12/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$535.98M$2.2849.985.71N/A7.43%11.00%3.35%4/29/2025 (Estimated)
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$12.67M$0.14N/A39.82N/A-5.42%-8.32%-3.40%4/29/2025 (Estimated)

Latest TARO, LEGN, TGTX, and SRPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/11/2025Q4 2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.39$0.07+$0.46$0.07$179.00 million$186.50 million
3/3/2025Q4 2024
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.08$0.15+$0.07$0.15$100.67 million$108.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Legend Biotech Co. stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.27
4.98
4.90
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.93
3.84
3.03
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.27
4.59
3.91

Institutional Ownership

CompanyInstitutional Ownership
Legend Biotech Co. stock logo
LEGN
Legend Biotech
70.89%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
91.40%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Legend Biotech Co. stock logo
LEGN
Legend Biotech
1,070183.65 million182.60 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
84097.03 million88.17 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290157.07 million139.32 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$33.24 +1.72 (+5.46%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$32.50 -0.74 (-2.23%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$62.47 +0.56 (+0.90%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$57.08 -5.39 (-8.62%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$39.82 +2.07 (+5.48%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$38.78 -1.04 (-2.61%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.